Uncategorized

RANBAXY LOSES TO PFIZER IN THE UK


Certainly breaking news!! For those coming in late on this (in true Phantom style), Ranbaxy challenged Pfizer’s 10 billion anti-cholestrol dollar drug (Lipitor) patent, arguing that it was invalid. It was succesful in Austria but lost just yesterday in the UK. A decision is awaited in the US, which incidentally is the main market and where experts expect Pfizer to win (not too surprising, since the US is more pro-patent than is the UK). The UK loss is therefore a…


Read More »